Psychosocial Influences in Oncology: An Expanded Model of Biobehavioral Mechanisms

Psychoneuroimmunology, Two-Volume Set

Volumn 2, Issue , 2007, Pages 869-895

  Lutgendorf, Susan K ^a   Costanzo, Erin S ^b   Siegel, Scott D ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b E11 SSH   (United States)

^c Department of Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947224225     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088576-3/50048-4     Document Type: Chapter

References (250)

1. Abercrombie H.C., Giese-Davis J., Sephton S., Epel E.S., Turner-Cobb J.M., Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 2004, 29:1082-1092.
2. Abulafia O., Triest W., Sherer D. Angiogenesis in malignancies of the female genital tract. Gyn. Oncol. 1999, 72:220-231.
3. American Cancer Society Cancer Facts and Figures 2005, Author, Atlanta, GA.
4. Andersen B., Farrar W.B., Golden-Kreutz D., Kutz L.A., MacCallum R., Courtney M.E., et al. Stress and immune responses after surgical treatment for regional breast cancer. J. Natl. Cancer Inst. 1998, 90:30-36.
5. Andersen B., Farrar W.B., Golden-Kreutz D.M., Glaser R., Emery C.F., Crespin T.R., et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J. Clin. Oncol. 2004, 22:3570-3580.
6. Andersen B., Kiecolt-Glaser J., Glaser R. A biobehavioral model of cancer stress and disease course. Am. Psychol. 1994, 49:389-404.
7. Andrykowski M.A., Brady M.J., Henslee-Downey P.J. Psychosocial factors predictive of survival after allogeneic bone marrow transplantation for leukemia. Psychosom. Med. 1994, 56:432-439.
8. Ansell S.M., Li C.-Y., Lloyd R.V., Phyliksy R.L. Epstein-Barr virus infection in Richter's transformation. Am. J. Hematol. 1999, 60:99-104.
9. Antoni M.H. Psychoneuroendocrinology and psychoneuroimmunology of cancer. Plausible mechanisms worth pursuing?. Brain Behav. Immun. 2003, 17:84-91.
10. Antoni M.H., Goodkin K. Host moderator variables in the promotion of cervical neoplasia-I. Personality facets. J. Psychosom. Res. 1988, 33:327-338.
11. Antoni M.H., Goodkin K. Host moderator variables in the promotion of cervical neoplasia-II. Dimensions of life stress. J. Psychosom. Res. 1989, 33:457-467.
12. Bando H., Weich H.A., Brokelmann M., Horiguchi S., Funata N., Ogawa T., et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br. J. Cancer 2005, 92(3):553-561.
13. Barlozzari T., Leonhardt J., Wiltrout R., Herbreman R., Reynolds C. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J. Immunol. 1985, 134:2783-2789.
14. Barraclough J., Pinder P., Cruddas M., Osmond C., Taylor I., Perry M. Life events and breast cancer prognosis. British Medical Journal 1992, 304:1078-1081.
15. Bellinger D., Lorton D., Lubahn C., Felten D. Innervation of lymphoid organs-association of nerves with cells of the immune system and their implications in disease. Psychoneuroimmunology 2001, vol. 1:55-111. Academic Press, San Diego. 3rd ed. R. Ader, D. Felten, N. Cohen (Eds.).
16. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav. Immun. 2003, 17:27-36.
17. Ben-Eliyahu S., Page G. In vivo assessment of natural killer cell activity in rats. Prog. Neuroendocrine Immunol. 1992, 5:199-214.
18. Ben-Eliyahu S., Shakhar G., Page G.G., Stefanski V., Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and betaadrenoceptors. Neuroimmunomodulation 2000, 8:154-164.
19. Berek J.S., Chung C., Kaldi K., Watson H.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 1991, 164:1038-1042.
20. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metallo-proteinase-9 trigg.
21. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav. Immun. 2002, 16:622-653.
22. Blake-Mortimer J.S., Sephton S.E., Carlson R.W., Stites D., Spiegel D. Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J. 2004, 10:195-199.
23. Bleiker E.M., Van der Ploeg H.M., Hendriks J.H., Ader H.J. Personality factors and breast cancer development: a prospective longitudinal study. J. Natl. Cancer Inst. 1996, 88:1478-1482.
24. Bovbjerg D., Redd W.H., Maier L.A., Holland J.C., Lesko L.M., Niedzwiecki D., et al. Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. J. Consut. Clin. Psychol. 1990, 58:153-157.
25. Bovbjerg D., Valdimarsdottir H. Familial cancer, emotional distress, and low natural cytotoxic activity in healthy women. Ann. Oncol. 1993, 4:745-752.
26. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
27. Bower J.E., Ganz P.A., Fahey J.L., Belin T.R., Tao M.L. Mechanisms of fatigue during radiation therapy for breast and prostate cancer. American Psychosomatic Society Annual Meeting 2005, Paper presented at the.
28. Brown J.E., Butow P.N., Culjak G., Coates A.S., Dunn S.M. Psychosocial predictors of outcome; time to relapse and survival in patients with early stage melanoma. Brit. J. Cancer 2000, 83:1448-1453.
29. Brown L., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
30. Brown M.R., Blanchette J.O., Kohn E.C. Angiogenesis in ovarian cancer. Balliere's Clin. Obstet. Gyn. 2000, 14:901-918.
31. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur. Resp. J. 1998, 11:173-178.
32. Buddeberg C., Sieber M., Wolf C., Landolt-Ritter C., Richter D., Steiner R. Coping strategies and 10-year outcome in early breast cancer. J. Psychosom. Res. 1997, 43:625-626.
33. Butow P.N., Coates A.S., Dunn S.M. Psychosocial predictors of survival in metastatic melanoma. J. Clin. Oncol. 1999, 17:2256-2263.
34. Butow P.N., Hiller J.E., Price M.A., Thackway S.V., Kricker A., Tennant C.C. Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J. Psychosom. Res. 2000, 49:169-181.
35. Byrnes D., Antoni M., Goodkin K., Efantis-Potter J., Asthana D., Simon T., et al. Stressful events, pessimism, natural killer cell cytotoxicity, and cytotoxic/suppressor T cells in HIV+ black women at risk for cervical cancer. Psychosom. Med. 1998, 60:714-722.
36. Cacioppo J., Ernst J., Burleson M., McClintock M., Malarkey W., Hawkley L., et al. Lonely traits and concomitant physiological processes: the MacArthur social neuroscience studies. Int. J. Psychophysiol. 2000, 35:143-154.
37. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-A in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol. 2002, 26:643-662.
38. Carlson L.E., Speca M., Patel K.D., Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom. Med. 2003, 65:571-581.
39. Cassileth B.R. Stress and the development of breast cancer: a persistent and popular link despite contrary evidence. Cancer 1996, 77:1015-1016.
40. Cassileth B.R., Walsh W.P., Lusk E.J. Psychosocial correlates of cancer survival: subsequent report 3 to 8 years after cancer diagnosis. J. Clin. Oncol. 1988, 6:1753-1759.
41. Chen C.C., David A.S., Nunnerleym H., Michell M., Dawson J.L., Berry H., et al. Adverse life events and breast cancer: case-control study. Brit. Med. J. 1995, 311:1527-1530.
42. Chopra V., Dinh T.V., Hannigan E. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest. 1998, 16:152-159.
43. Chrousos G. The concepts of stress and stress system disorders. JAMA 1992, 267:1244-1252.
44. Cohen L., Marshall G.D.J., Cheng L., Agarwal S.K., Wei Q. DNA repair capacity in healthy medical students during and after exam stress. J. Behav. Med. 2000, 23:531-544.
45. Cohen M., Klein E., Kuten A., Fried G., Zinder O., Pollack S. Increased emotional distress in daughters of breast cancer patients is associated with decreased natural cytotoxic activity, elevated levels of stress hormone. Int. J. Cancer 2002, 100:347-354.
46. Cohen S., Rabin B. Psychological stress, immunity, and cancer. J. Natl. Cancer Inst. 1998, 90:3-4.
47. Cohen S., Wills T. Stress, social support, and the buffering hypothesis. Psychol. Bull. 1985, 98:310-357.
48. Cooper B.C., Ritchie J.M., Broghammer C.L.W., Coffin J., Sorosky J.I., Buller R.E., et al. Preoperative serum vascular endothelial growth factor (VEGF) levels: significance in ovarian cancer. Clin. Cancer Res. 2002, 8:3193-3197.
49. Costanzo E.S., Lutgendorf S.K., Sood A.K., Anderson B., Sorosky J., Lubaroff D.M. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005, 104:305-313.
50. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
51. Cruess D., Antoni M., Kumar M., Schneiderman N. Reductions in salivary cortisol are associated with mood improvement during relaxation training among HIV-seropositive men. J. Behav. Med. 2000, 23:107-122.
52. Cunningham A.J., Edmonds C.V., Jenkins G.P., Pollack H., Lockwood G.A., Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology 1998, 7:508-517.
53. Daly M., Obrams G.I. Epidemiology and risk assessment for ovarian cancer. Sem. Oncol. 1998, 25:255-264.
54. Dankbar B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R., et al. Vascular endothelial growth factor and interleu-kin-6 in paracrine tumor-stromal cells interactions in multiple myeloma. Blood 2000, 95(8):2630-2636.
55. Dattore P.J., Shontz F.C., Coyne L. Premorbid personality differentiation of cancer and noncancer groups: a test of the hypothesis of cancer proneness. J. Consult. Clin. Psychol. 1980, 48:388-394.
56. Dedert E.A., Studts J.L., Weissbecker I., Salmon P.G., Banis P.L., Sephton S.E. Religiosity may help preserve the cortisol rhythm in women with stress-related illness. Int. J. Psychiatry Med. 2004, 34:61-77.
57. DeKeyser F.G., Wainstock J.M., Rose L., Converse P.J., Dooley W. Distress, symptom distress, and immune function in women with suspected breast cancer. Onc. Nurs. Forum 1998, 25:1415-1422.
58. Dentino A.N., Pieper C.F., Rao M.K., Currie M.S., Harris T., Blazer D.G., et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J. Am. Ger. Soc. 1999, 47:6-11.
59. Deuschle M., Schweiger U., Weber B., Gotthardt U., Korner A., Schmider J., et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J. Clin. Endocrinol. Metab. 1997, 82:234-238.
60. Deuschle M., Weber B., Colla M., Depner M., Heuser I. Effects of major depression, aging and gender upon calculated diurnal free plasma cortisol concentrations: a re-evaluation study. Stress 1998, 2:281-287.
61. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-g receptors. Immunity 1994, 1:447-456.
62. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Rev. Cancer 2004, 4:11-22.
63. Duijts S.F.A., Zeegers M.P.A., Borne B.V. The association between stressful life events and breast cancer risk: a meta-analysis. Intl. J. Cancer 2003, 107:1023-1029.
64. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
65. Edelman S., Lemon J., Bell D.R., Kidman A.D. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 1999, 8:474-481.
66. Edwards J.R., Cooper C.L., Pearl S.G., De Paredes E.S.O., Leary T., Wilhelm M.C. The relationship between psychosocial factors and breast cancer: some unexpected results. Behav. Med. 1990, 16:5-14.
67. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Ned Tijdechr Geneeskd 1909, 5:273-290.
68. Elenkov I.J., Chrousos G.P. Stress hormones, proin-flammatory and antiinflammatory cytokines, and autoimmunity. Ann. N.Y. Acad. Sci. 2002, 966:290-303.
69. Elenkov I.J., Chrousos G.P., Wilder R.L. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann. N. Y. Acad. Sci. 2000, 917:94-105.
70. Epping-Jordan J., Compas B., Howell D. Predictors of cancer progression in young adult men and women: avoidance, intrusive thoughts, and psychological symptoms. Health Psychol. 1994, 13:539-547.
71. Faller H., Bulzebruck H., Drings P., Lang H. Coping, distress, and survival among patients with lung cancer. Arch. Gen. Psychiatry 1999, 56:756-762.
72. Fawzy F.I., Canada A.L., Fawzy R.N. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch. Gen. Psychiatry 2003, 60:100-103.
73. Fawzy F.I., Cousins N., Fawzy N.W., Kemeny M.E., Elashoff R., Morton D. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch. Gen. Psychiatry 1990, 47:720-725.
74. Fawzy F.I., Fawzy N.W., Hyun C.S., Elashoff R., Guthrie D., Fahey J.L., et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch. Gen. Psychiatry 1993, 50:681-689.
75. Fawzy F.I., Kemeny M.E., Fawzy N.W., Elashoff R., Morton D., Cousins N., et al. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch. Gen. Psychiatry 1990, 47:729-735.
76. Fidler I.J. Mol. biol. cancer: invasion and metastasis 1997, Lippincott-Raven, Philadelphia.
77. Folkman J. What is the evidence that tumors are angiogenesis dependant?. J. Natl. Cancer Inst. 1990, 82:4-6.
78. Folkman J. Tumor angiogenesis. The Molecular Basis of Cancer 1995, 206-232. W.B. Saunders, Philadelphia. J. Mendelsohn, P. M. Howley, M. A. Israel, L. A. Liotta (Eds.).
79. Forlenza M.J., Latimer J.J., Baum A. The effects of stress on DNA repair capacity. Psychol. Health 2000, 15:881-891.
80. Forsen A. Psychosocial stress as a risk for breast cancer. Psychotherapy & Psychosomatics 1991, 55:176-185.
81. Fox B.H. A hypothesis about Spiegel et al.'s 1989 paper on psychosocial intervention and breast cancer survival. Psychooncology 1998, 7:361-370.
82. Fox C.M., Harper A.P., Hyner G.C., Lyle R.M. Loneliness, emotional repression, marital quality, and major life events in women who develop breast cancer. J. Community Health 1994, 19:467-482.
83. Fredrikson M., Furst C.J., Lekander M., Rotstein S., Blomgren H. Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer. Brain Behav. Immun. 1993, 7:79-90.
84. Fu L., Palican H., Liu J., Huang P., Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002, 111:41-50.
85. Funch D.P., Marshall J. The role of stress, social support and age in survival from breast cancer. J. Psychosom. Res. 1983, 27:77-83.
86. Gabrilovich D.I., Chen H.L., Girgis K.R. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
87. Garcia-Lora A., Algarra I., Garrido F. MHC class I antigens, immune surveillance, and tumor escape. J. Cell. Physiol. 2003, 195:346-355.
88. Garland M.R., Lavelle E., Doherty D., Golden-Mason L., Fitzpatrick P., Hill A., et al. Cortisol does not mediate the suppressive effects of psychiatric morbidity on natural killer cell activity: a cross-sectional study of patients with early bre. Psychol. Med. 2004, 34:481-490.
89. Garner W., Minton J., James A., Hoffman C. Human breast cancer and impaired NK cell function. J. Surg. Oncol. 1983, 24:64-66.
90. Garssen B. Psychological factors and cancer development: evidence after 30 years of research. Clin. Psychol. Rev. 2004, 24:315-338.
91. Geinitz H., Zimmermann F., Stoll P. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Intl. J. Radiat. Oncol. Biol. Phys. 2001, 51:691-698.
92. Geyer S. Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. Journal of Psychosomatic Research 1991, 35:355-363.
93. Geyer S. Life events, chronic difficulties and vulnerability factors preceding breast cancer. Social Science & Medicine 1993, 37:1545-1555.
94. Giese-Davis J., Sephton S., Abercrombie H., Duran R., Spiegel D. Repression and high anxiety are associated with aberrant diurnal cortisol rhythms in women with metastatic breast cancer. Health Psychol. 2004, 23:645-650.
95. Giraldi T., Rodani M.G., Cartei G., Grassi L. Psychosocial factors and breast cancer: a 6-year Italian follow-up study. Psychother. Psychosom. 1997, 66:229-236.
96. Glaser R., Padgett D., Litsky M., Baiocchi R., Yang E., Chen M., et al. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav. Immun. 2005, 19:91-103.
97. Glaser R., Pearl D.K., Kiecolt-Glaser J.K., Malarkey W.B. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress. Psychoneuroendocrinology 1994, 19:765-772.
98. Glaser R., Thorn B., Tarr K., Kiecolt-Glaser J., D'Ambrosio S. Effects of stress on methyl-transferase synthesis: an important DNA repair enzyme. Health Psychol. 1985, 4:403-412.
99. Goedegebuure P.S., Douville C.C., Doherty J.M., Linehan D.C., Lee K.Y., Ganguly E.K., et al. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Cell. Immunol. 1997, 175:150-156.
100. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical de pression: high vs low CRH/NE states. Mol. Psychiatry 2002, 7:254-275.
101. Goodkin K., Antoni M., Blaney P. Stress and hopelessness in the promotion of cervical intraepithelial neoplasia to invasive squamous cell carcinoma of the cervix. J. Psychosom. Res. 1986, 30:67-76.
102. Goodkin K., Antoni M., Helder L., Sevin B. Psychosocial factors in the progression of cervical intraepithelial neoplasia -CIN. J. Psychosom. Res. 1993, 37:554-557.
103. Goodwin P.J., Leszcz M., Ennix M.E.A. The effect of group psychosocial support on survival in metastatic breast cancer. N. Engl. J. Med. 2001, 345:1719-1726.
104. Grassi L., Cappellari L. State and trait psychological characteristics of breast cancer patients. New Trends Exp. Clin. Psychiatry 1988, 4:99-109.
105. Greenberg D., Gray J., Mannix C., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom Manage. 1993, 8:196-200.
106. Greer S., Morris T. Psychological attributes of women who develop breast cancer: a controlled study. J. Psychosom. Res. 1975, 19:147-153.
107. Greer S., Morris T. The study of psychological factors in breast cancer: problems of method. Soc. Sci. Med. 1978, 12:129-134.
108. Greer S., Morris T., Pettingale K. Psychological response to breast cancer: effect on outcome. Lancet 1979, 335:49-50.
109. Greer S., Morris T., Pettingale K., Haybittle J. Psychological response to breast cancer and 15 year outcome. Lancet 1990, 335:49-50.
110. Greer S., Watson M. Towards a psychobiological model of cancer: psychological considerations. Soc. Sci. Med. 1985, 20:773-777.
111. Gruber B., Hersh S., Hall N., Waletzky L., Kunz J., Carpenter J., et al. Immunologic responses of breast cancer patients to behavioral interventions. Biofeedback Self-Regul. 1993, 18:1-22.
112. Hahn R.C., Petitti D.B. Minnesota multiphasic personality inventory-rated depression and the incidence of breast cancer. Cancer 1988, 61:845-848.
113. Hamaoka T., Fujiwara H. Phenotypically and functionally distinct T-cell subsets in anti-tumor responses. Immunol. Today 1987, 8:267-269.
114. Henney A., Ye S., Zhang B., Jormsjo S., Whatling C., Eriksson P., et al. Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression. Ann. N.Y. Acad. Sci. 2000, 902:27-37.
115. Heo D., Whiteside T., Kanbour A., Herberman R. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1) -positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovaria. J. Immunol. 1988, 140:4042-4049.
116. Hirte H., Clark D. Factors determining the ability of cytokine-activated killer cells to lyse human ovarian carcinoma targets. Cell. Immunol. 1991, 136:122-132.
117. Hosaka T., Tokuda Y., Sugiyama Y., Hirai K., Okuyama T. Effects of a structured psychiatric intervention on immune function of cancer patients. Tokai J. Exp. Clin. Med. 2000, 25:183-188.
118. House J.S., Landis K.R., Umberson D. Social relationships and health. Science 1988, 241:540-545.
119. Hsu M.Y., Meier F., Meenhard H. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002, 70:522-536.
120. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Nat. Cancer Inst. 2002, 94:1134-1142.
121. Illman J., Corringham R., Robinson D.J., Davis H.M., Rossi J.F., Cella D., et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression. J. Supportive Oncol. 2005, 3:37-50.
122. Inoue M., Itoh H., Tanaka T., Chun T., Doi K., Fukunaga Y., et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-. Arterioscler. Thromb. Vasc. Biol. 2001, 21:560-566.
123. Ioannides C., Freedman R., Platsoucas C., Rashed S., Kim Y. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 1991, 146:1700-1707.
124. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav. Immun. 2002, 16(1):1-16.
125. Irwin M., Pike J., Oxman M.N. Effects of a behavioral intervention, Tai Chi Chih, on varicella-zoster virus specific immunity and health functioning in older adults. Psychosom. Med. 2003, 65:824-830.
126. James G.D., Berge-Landry H., Valdimarsdottir H.B., Montgomery G., Bovbjerg D.H. Urinary catecholamine levels in daily life are elevated in women at familial risk of breast cancer. Psychoneuroendocrinology 2004, 29:831-838.
127. Jensen M.R. Psychobiological factors predicting the course of breast cancer. J. Pers. 1987, 55:317-342.
128. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
129. Kiecolt-Glaser J., Fisher L., Ogrocki P., Stout J., Speicher C., Glaser R. Marital quality, marital disruption, and immune function. Psychosom. Med. 1987, 49:13-34.
130. Kiecolt-Glaser J.K., Glaser R. Psychoneuroimmunology and cancer: fact or fiction?. Eur. J. Cancer 1999, 35:1603-1607.
131. Kiecolt-Glaser J.K., Preacher K.J., MacCallum R.C., Atkinson C., Malarkey W.B., Glaser R. Chronic stress and agerelated increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. USA 2003, 100:9090-9095.
132. Kiecolt-Glaser J.K., Stephens R.E., Lipetz P.D., Speicher C.E., Glaser R. Distress and DNA repair in human lymphocytes. J. Behav. Med. 1985, 8:311.
133. Knekt P., Raitasalo R., Heliovaara M., Lehtinen V., Pukkala E., Teppo L., et al. Elevated lung cancer risk among persons with depressed mood. Am. J. Epidemiol. 1996, 144:1096-1103.
134. Kogon M.M., Biswas A., Pearl D., Carson R.W., Spiegel D. Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cancer 1997, 80:225-230.
135. Kowalczyk D.W. Tumors and the danger model. Acta Biochimica Polonica 2002, 49:295-302.
136. Kuchler T., Henne-Bruns D., Rappat S., Graul J., Holst K., Williams J.I., et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepato Gastroenterol. 1999, 46:322-335.
137. Kurcrock R. The role of cytokines in cancer-related fatigue. Cancer 2001, 92:1684-1688.
138. Kvikstad A., Vatten L.J. Risk and prognosis of cancer in middle-aged women who have experienced the death of a child. International Journal of Cancer 1996, 67:165-169.
139. Lai P., Rabinowich H., Crowley-Nowick P., Bell M., Mantovani G., Whiteside T. Alteration in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 1996, 2:161-173.
140. Lee K.H., Panelli M.C., Kim C.J., Riker A.I., Bettinotti M.P., Roden M.M. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 1998, 161:4183-4194.
141. Lekander M., Furst C., Rotstein S., Blomgren H., Fredrikson M. Social support and immune status during and after chemotherapy for breast cancer. Acta Oncologica 1996, 35:31-37.
142. Lekander M., Furst C.J., Rotstein S., Hursti T.J., Fredrikson M. Immune effects of relaxation during chemotherapy for ovarian cancer. Psychother. Psychosom. 1997, 66:185-191.
143. Levav I., Kohn R., Iscovich J., Abramson J.H., Tsai W.Y., Vigdorovich D. Cancer incidence and survival following bereavement. American Journal of Public Health 2000, 90:1601-1607.
144. Levy S., Herberman R., Lee J., Whiteside T., Kirkwood J., McFeeley S. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Nat. Immun. Cell. Growth Regul. 1990, 9:313-324.
145. Levy S., Herberman R., Lippman M., D'Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J. Clin. Oncol. 1987, 5:348-353.
146. Levy S., Herberman R., Lippman M., D'Angelo T., Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav. Med. 1991, 17:67-75.
147. Levy S., Herberman R., Maluish A., Schlein B., Lippman M. Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. Health Psychol. 1985, 4:99-113.
148. Lewin M., Bredow S., Sergeyev N., Marecos E., Bogdanov A., Weissleder R. In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int. J. Cancer 1999, 83:798-802.
149. Li G.Y., Yao K.T., Glaser R. Sister chromatid exchange and nasopharyngeal carcinoma. Int. J. Cancer 1989, 43:613-618.
150. Li R., Ruttinger D., Li R., Si L.S., Wang Y.L. Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbeck's Arch. Surg. 2003, 388:406-412.
151. Licinio J., Gold P.W., Wong M.L. A molecular mechanism for stress-induced alterations in susceptibility to disease. Lancet 1995, 346:104-106.
152. Lillberg K., Verkasalo P.K., Kaprio J., Teppo L., Helenius H., Koskenvuo M.S. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. American Journal of Epidemiology 2003, 157:415-423.
153. Linkins R.W., Comstock G.W. Depressed mood and development of cancer. Am. J. Epidemiol. 1990, 132:962-972.
154. Lotzova E., Savary C., Freedman R., Bowen J. Natural immunity against ovarian tumors. Comp. Immunol. Microbio. Infect. Dis. 1986, 9:269-275.
155. Lutgendorf S., Anderson B., Buller R., Sorosky J., Lubaroff D. Interleukin-6 and social support in gynecologic cancer patients. Int. J. Behav. Med. 2000, 7:127-142.
156. Lutgendorf S., Garand L., Buckwalter K., Tripp-Reimer T., Hong S., Lubaroff D. Life stress, mood disturbance, and elevated IL-6 in healthy older women. J. Gerontol. A. Biol. Sci. Med. Sci. 1999, 54. M434-M439.
157. Lutgendorf S.K., Sood A.K., Anderson B., McGinn S., Maiseri H., Dao M., et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J. Clin Oncol. 2005, 23:7106-7113.
158. Lutgendorf S.K., Cole S., Costanzo E., Bradley S., Coffin J., Jabbari S., et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 2003, 9:4514-4521.
159. Lutgendorf S.K., Johnsen E., Cooper B., Anderson B., Sorosky J.I., Buller R.E., et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002, 95:808-815.
160. Machein M., Kullmer J., Ronicke V., Machein U., Krieg M., Damert A., et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol. Appl. Neurobiol. 1999, 25:104-112.
161. Maier S., Watkins L. Cytokines for psychologists: implications of bidirectional immune to brain communication for understanding behavior, mood, and cognition. Psychol. Rev. 1998, 105:83-107.
162. Marshall J., Funch D.P. Social environment and breast cancer: a cohort analysis of patient survival. Cancer 1983, 52:1546-1550.
163. Martikainen P., Valkonen T. Mortality after death of a spouse: rates and causes of death in a large Finnish cohort. American Journal of Public Health 1996, 86:1087-1093.
164. Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 1994, 12:991-1045.
165. Maunsell E., Brisson J., Deschenes L. Social support and survival among women with breast cancer. Cancer 1995, 76:631-637.
166. Maunsell E., Brisson J., Mondor M., Verreault R., Deschenes L. Stressful life event and survival after breast cancer. Psychosomatic Medicine 2001, 63:306-315.
167. McGee R., Williams S., Elwood M. Depression and the development of cancer: a meta-analysis. Soc. Sci. Med. 1994, 38:187-192.
168. McGee R., Williams S., Elwood M. Are life events related to the onset of breast cancer?. Psychol. Med. 1996, 26:441-447.
169. McGregor B., Antoni M., Boyers A., Alferi S., Blomberg B., Carver C. Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer. J. Psychosom. Res. 2004, 56:1-8.
170. McKenna M., Zevon M., Corn B., Rounds J. Psychological factors and the development of breast cancer: a metaanalysis. Health Psychol. 1999, 18:520-531.
171. Melief C. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 1992, 58:143-175.
172. Melief C., Kast W. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Cancer Biol. 1991, 2:347-353.
173. Miller G.E., Cohen S., Ritchey A.K. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol. 2002, 21:531-541.
174. Miller R.A. The aging immune system: primer and prospectus. Science 1996, 273:70-74.
175. Molassiotis A., Van den Akker O.B.A., Milligan D.W., Goldman J.M. Symptom distress, coping style and biological variables as predictors of survival after bone marrow transplantation. J. Psychosom. Res. 1997, 42:275-285.
176. Mormont M., Levi F. Circadian system alterations during cancer processes: a review. Int. J. Cancer 1997, 70:241-247.
177. Morris T., Pettingale K.W., Haybittle J.L. Psychological response to cancer diagnosis and disease outcome in patients with breast cancer and lymphoma. Psychooncology 1992, 1:105-114.
178. Murphy K.C., Jenkins P.L., Whittaker J.A. Psychosocial morbidity and survival in adult bone marrow transplant recipients-a follow-up study. Bone Marrow Transplant. 1996, 18:199-201.
179. Nan K., Wei Y., Zhou F.L., Li C.L., Sui C.G., Hui L.Y., et al. Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers. World J. Gastroenterol. 2004, 10:268-272.
180. Naylor M.S., Stamp G.W., Davies B.D., Balkwill F.R. Expression and activity of MMPS and their regulators in ovarian cancer. Intl. J. Cancer 1994, 58:50-56.
181. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration, and invasion of human ovarian carcinoma. Anticancer Res. 1997, 17:337-342.
182. Ohm J.E., Gabrilovich D.I., Sempowski G.D. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101:4878-4886.
183. Ornish D., Weidner G., Fair W.R., Marlin R., Pettengill E.B., Raisin C.J., et al. Intensive lifestyle changes may affect the progression of prostate cancer. Journal of Urology 2005, 174:1065-1070.
184. Osborne R.H., Sali A., Aaronson N.K., Elsworth G.R., Mdzewski B., Sinclair A.J. Immune function and adjustment style: do they predict survival in breast cancer?. Psychooncology 2004, 13:199-210.
185. Penn I. Posttransplant malignancies. Transplant Proc. 1999, 31:1260-1262.
186. Penninx B.W., Guralnik J.M., Pahor M., Ferrucci L., Cerhan J.R., et al. Chronically depressed mood and cancer risk in older persons. J. Natl. Cancer Inst. 1998, 90:1888-1893.
187. Persky V.W., Kempthorne-Rawson J., Shekelle R.B. Personality and risk of cancer: 20-year follow-up of the Western Electric study. Psychosom. Med. 1987, 49:435-449.
188. Petticrew M., Bell R., Hunter D. Influence of psychological coping on
189. Petticrew M., Fraser J.M., Regan M.F. Adverse lifeevents and risk of breast cancer: a meta-analysis. Br. J. Health Psychol. 1999, 4:1-17.
190. Pettingale K.W. Coping and cancer prognosis. J. Psychosom. Res. 1984, 28:363-364.
191. Pettingale K.W., Burge C., Greer S. Psychological response to cancer diagnosis: I. Correlations with prognostic variables. J. Psychosom. Res. 1988, 32:255-261.
192. Pettingale K.W., Morris T., Greer S., Haybittle J. Mental attitudes to cancer: an additional prognostic factor. Lancet 1985, 1:750.
193. Phillips R.E. Immunology taught by Darwin. Nat. Immunol. 2002, 3:987-989.
194. Price M., Tennant C., Smith R., Butow P., Kennedy S., Kossoff M. The role of psychosocial factors in the development of breast carcinoma: PART 1. Cancer 2001, 91:679-685.
195. Protheroe D., Turvey K., Horgan K., Benson E., Bowers D., House A. Stressful life events and difficulties and onset of breast cancer: case-control study. Br. Med. J. 1999, 319:1027-1030.
196. Pruessner J.C., Hellhammer D.H., Kirschbaum C. Burnout, perceived stress, and cortisol responses to awakening. Psychosom. Med. 1999, 61:197-204.
197. Ramirez A.J., Craig T.K., Watson J.P., Fentiman I.S., North W.R., Rubens R.D. Stress and relapse of breast cancer. British Medical Journal 1989, 298:291-293.
198. Redwine L., Hauger R.L., Gillin J.C., Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J. Clin. Endocrinol. Metab. 2000, 85:3597-3603.
199. Reynolds P., Boyd P.T., Blacklow R.S., Jackson J.S., Greenberg R.S., Austin D.F., et al. The relationship between social ties and survival among black and white breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 1994, 3:253-259.
200. Reynolds P., Hurley S., Torres M., Jackson J., Boyd P.T., Chen V.W., et al. Use of coping strategies and breast cancer survival: results from the Black/White Cancer Survival study. Am. J. Epidemiol. 2000, 152:940-949.
201. Reynolds P., Kaplan G.A. Social connections and risk for cancer: prospective evidence from the Alameda County study. Behav. Med. 1990, 16:101-110.
202. Rigas J., Hoopes P., Meyer L., Smith E., Hammond S., Leopold K., et al. Fatigue linked to plasma cytokines in patients with lung cancer undergoing combined modality therapy. Proc. ASCO 1998, 17:68A.
203. Riley V. Mouse mammary tumors: alteration of incidence as apparent function of stress. Science 1975, 189:465-467.
204. Rivoltini L., Carrabba M., Huber V., Castelli C., Novellino L., Dalerba P., et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 2002, 188:97-113.
205. Roberts D., Anderson B., Lubaroff D. Stress and immunity at cancer diagnosis 1994, Unpublished doctoral dissertation, University of Iowa.
206. Rodrigue J.R., Pearman T.P., Moreb J. Morbidity and mortality following bone marrow transplantation: predictive utility of pre-BMT affective functioning, compliance, and social support stability. Intl. J. Behav. Med. 1999, 6:241-254.
207. Rowse D.L., Weinberg J., Bellward G.D., Emerman J.T. Endocrine mediation of psychosocial stressor effects on mouse mammary tumor growth. Cancer Lett. 1992, 65:85-93.
208. Sapolsky R.M., Donnelly T.M. Vulnerability to stressinduced tumor growth increases with age in rats: role of glucocorticoids. Endocrinol. 1985, 117:662-666.
209. Scambia G., Testa U., Benedetti P., Foti E., Nartucci R., Gadducci A., et al. Prognostic significance of IL-6 serum levels in patients with ovarian cancer. Br. J. Cancer 1995, 71:352-356.
210. Schantz S., Goephert H. Multimodal therapy and distant metastasis: the impact of NK cell activity. Arch. Otolaryngol. Head Neck Surg. 1987, 113:1207-1213.
211. Schapiro I.R., Ross-Petersen L., Saelan H., Garde K., Olsen J.H., Johansen C. Extraversion and neuroticism and the associated risk of cancer: a Danish cohort study. Am. J. Epidemiol. 2001, 153:757-763.
212. Schedlowski M., Jung C., Schimanski G., Tewes U., Schmoll H.J. Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: an exploratory study. Psychooncology 1994, 3:181-187.
213. Scherg H., Cramer I., Blohmke M. Psychosocial factors and breast cancer: a critical reevaluation of established hypotheses. Cancer Detect. Prev. 1981, 4:165-171.
214. Schondorf T., Engel H., Lindemann C., Kolhagen H., Von Rucker, A.Mallmann P. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynecological tumours. Cancer Immunol. Immunother. 1997, 44:88-96.
215. Schulz R., Bookwala J., Knapp J.E., Scheier M., Williamson G.M. Pessimism, age, and cancer mortality. Psychol. Aging 1996, 11:304-309.
216. Schwartsburd P.M. Age-promoted creation of a pro-cancer microenvironment by inflammation: pathogenesis of dyscoordinated feedback control. Mech. Aging Dev. 2004, 125:581-590.
217. Segerstrom S.C. Individual differences, immunity, and cancer: lessons from personality psychology. Brain Behav. Immun. 2003, 17(Suppl 1):92-97.
218. Sephton S., Koopman C., Schaal M., Thoresen C., Spiegel D. Spiritual expression and immune status in women with metastatic breast cancer: an exploratory study. Breast J. 2001, 7:345-353.
219. Sephton S., Sapolsky R.M., Kraemer H.C., Speigel D. Early mortality in metastatic breast cancer patients absent of abnormal diurnal cortisol rhythms. J. Natl. Cancer Inst. 1999, 92:994-1000.
220. Sephton S., Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease?. Brain Behav. Immun. 2003, 17:321-328.
221. Seymour K., Pettit S., O'Flaherty E., Charnley R.M., Kirby J.A. Selection of metastatic tumor phenotypes by host immune system. Lancet 1999, 353:1989-1991.
222. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
223. Smith B.D., Smith G.L., Carter D., Sasaki C.T., Haffty B.G. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 2000, 1(18):2046-2052.
224. Sood A., Landen C., Bhatty R., Thaker P., Lutgendorf S. Stress hormone mediated invasion of ovarian cancer cells. Psychosom. Med. 2004, 65:A14.
225. Spiegel D., Bloom G., Kramer J., Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989, 2:888-891.
226. Stetlow R.B. Repair deficient human disorders and human cancer. Nature 1978, 271:713-717.
227. Stommel M., Given B.A., Given C.W. Depression and functional status as predictors of death among cancer patients. Cancer 2002, 94:2719-2727.
228. Suls J., Fletcher B. The relative efficacy of avoidant and nonavoidant coping strategies: a meta-analysis. Health Psychol. 1985, 4:249-288.
229. Tartter P., Martinelli G., Steinberg B., Barron D. Changes in peripheral T cell subsets and natural killer cytotoxicity in relation to colon rectal cancer surgery. Cancer Detect. Prev. 1986, 89:359-364.
230. Temoshok L. Personality, coping style, emotion and cancer: towards an integrative model. Cancer Surv. 1987, 6:545-567.
231. Temoshok L., Heller B., Sagebiel R.W., Blois M.S., Sweet D.M., DiClemente R.J., et al. The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. J. Psychosom. Res. 1985, 29:139-153.
232. Thaker P., Lloyd M., Jennings N., Felix E., Gershenson D., Newman R., et al. Chronic stress promotes tumor growth and metastasis in ovarian carcinoma. Society of Gynecological Oncology 36th Annual Meeting 2005, Paper presented at.
233. Tjemsland L., Soreide J.A., Matre R., Malt U.F. Preoperative psychological variables predict immunological status in patients with operable breast cancer. Psychooncology 1997, 6:311-320.
234. Tomei L.D., Kiecolt-Glaser J.K., Kennedy S., Glaser R. Psychological stress and phorbol ester inhibition of radiationinduced apoptosis in human peripheral blood leukocytes. Psychiatry Res. 1990, 33:59-71.
235. Tschuschke V., Hertenstein B., Arnold R., Bunjes D., Denzinger R., Kaechele H. Associations between coping and survival time of adult leukemia patients receiving allogenic bone marrow transplantation: results of a prospective study. J. Psychosom. Res. 2001, 50:277-285.
236. Turner-Cobb J., Koopman C., Rabinowitz J., Terr A., Sephton S.E., Spiegel D. The interaction of social network size and stressful life events predict delayed-type hyper-sensitivity among women with metastatic breast cancer. Int. J. Psychophysiol. 2004, 54:241-249.
237. Turner-Cobb J.M., Sephton S.E., Koopman C., Blake-Mortimer J., Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom. Med. 2000, 62:337-345.
238. Valdimarsdottir H., Zakowski S.G., Gerin W., Mamakos J., Pickering T., Bovbjerg D.H. Heightened psychobiological reactivity to laboratory stressors in healthy women at familial risk for breast cancer. J. Behav. Med. 2002, 25:51-65.
239. Vujaskovic Z., Feng Q.F., Rabbani Z.N., Anscher M.S., Samulski T.V., Brizel D.M. Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. Radiat. Res. 2002, 157:656-660.
240. Watson M., Haviland J.S., Greer S., Davidson J., Bliss J.M. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999, 354:1331-1336.
241. Weihs K.L., Enright T.M., Simmens S.J., Reiss D. Negative affectivity, restriction of emotions, and site of metastases predict mortality in recurrent breast cancer. J. Psychosom. Res. 2000, 49:59-68.
242. Whiteside T., Herberman R. The role of natural killer cells in human disease. Clin. Immun. Immunopathol. 1989, 53:1-23.
243. Wu S., Rodabaugh K., Martinez-Maza O., Watson J.M., Silberstein D.S., Boyer C.M., et al. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am. J. Obstet. Gynecol. 1992, 166:997-1007.
244. Wu W. Social isolation stress enhanced liver metastasis of murine colon 26-L5 carcinoma cells by suppressing immune responses in mice. Life Sci. 2000, 66:1827-1838.
245. Wu W., Yamura T., Murakami K., Ogasawara M., Hayashi K., Murata J., et al. Involvement of TNFá in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress. Oncol. Res. 1999, 11:461-469.
246. Yang E., Bane C.M., MacCallum R.C., Kiecolt-Glaser J.K., Malarkey W.B., Glaser R. Stress-related modulation of matrix metalloproteinase expression. J. Neuroimmunol. 2002, 133:144-150.
247. Yang E., Glaser R. Stress-induced immunomodulation: implications for tumorigenesis. Brain Behav. Immun. 2003, 17:S37-S40.
248. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
249. Zhou G., Zhengbin L., McCadden J.D., Levitsky H.I., Marson A.L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exper. Med. 2004, 200:1581-1592.
250. Zorilla E.P., Luborsky L., McKay J.R. The relationship of depression and stressors to immunological assays: a metaanalytic review. Brain Behav. Immun. 2001, 15:199-226.